BRAF and non-small cell lung carcinoma: For BRAF-V600E-mutant NSCLC, the combination of oral serine/threonine kinase inhibitors dabrafenib and trametinib obtained significant responses in both the first (ORR 68%) and second (ORR 64%) line in the phase II BRF113928 study, and it is considered standard of care [56].